Peptide Drug Interactions: A Practical Guide

Why this article is structured by your medication, not by peptide

The standard format for drug interaction information is "for Peptide X, here are the interactions to watch for." That format makes sense for prescribers but it fails the most common real-world use case: you're already on a medication, you're considering a peptide, and you want to know if there's a problem. The peptide world has dozens of peptides; you have a finite list of medications you're actually on.

This article inverts the standard structure. We walk through the medications and conditions most likely to produce meaningful interactions, then explain which peptides matter for each. If you're on warfarin, you don't need to read every peptide page hoping the warfarin interaction is mentioned — you read the anticoagulant section here and get the practical list.

For the broader safety framework, see our pillar safety article. For peptides with specific high-caution signals beyond interactions, see our high-caution peptides article. Together, the three articles cover the safety landscape with the specificity that informed decision-making requires.

If you take insulin or sulfonylureas

The interaction

GLP-1 receptor agonists — semaglutide, liraglutide, tirzepatide, dulaglutide, exenatide, lixisenatide and the emerging dual/triple agonists — substantially increase the risk of hypoglycemia when combined with insulin or sulfonylureas (glipizide, glyburide, glimepiride).

This is the most clinically meaningful and most quantitatively documented interaction in the peptide space. The mechanism is straightforward: GLP-1 agonists improve insulin sensitivity, reduce glucagon, and slow gastric emptying. Combined with exogenous insulin or insulin-stimulating sulfonylureas, the additive glucose-lowering can produce severe hypoglycemia, particularly during titration or after meals.

What to actually do

• Endocrinologist or primary-care input is essential before starting a GLP-1 if you're on insulin or sulfonylureas. This is not the situation to self-prescribe.
• Insulin doses often need to be reduced at GLP-1 initiation — sometimes by 20-40% depending on baseline A1c and dose.
• Sulfonylureas are often discontinued or reduced when starting a GLP-1 because of redundant mechanism.
• Continuous glucose monitoring is genuinely valuable during the transition period.
• If you experience hypoglycemic symptoms (shakiness, sweating, confusion, irritability), check blood glucose immediately and treat with fast-acting carbohydrate. Repeated hypoglycemia is a signal to adjust doses, not to push through.

If you take opioids or anti-emetic medications

The interaction

GLP-1 receptor agonists slow gastric emptying. Opioids also slow gastric emptying and decrease GI motility. The combination can produce severe gastroparesis — nausea, vomiting, constipation, and inability to tolerate food. Anti-emetics that also affect motility (ondansetron is generally fine; metoclopramide can have complex interactions) require attention.

What to actually do

• If you're on chronic opioid therapy, talk to your prescribing physician before starting a GLP-1. The combination is not necessarily contraindicated but warrants planning.
• Constipation prophylaxis becomes more important — adequate fiber, hydration, and possibly a stool softener or osmotic laxative during dose titration.
• If severe nausea/vomiting develops, the appropriate response is dose reduction of the GLP-1, not increasing anti-emetic doses to push through. Severe gastroparesis from the combination can be debilitating.
• Surgical procedures become more complex — see the surgery section below.

If you have surgery or any procedure with sedation coming up

The interaction

This is the highest-importance current safety topic in the GLP-1 space, and it's frequently missed. GLP-1 receptor agonists slow gastric emptying. During induction of anesthesia, retained stomach contents can be aspirated into the lungs, producing serious pulmonary complications.

The American Society of Anesthesiologists published consensus guidance in 2023 (updated 2024) recommending that GLP-1 agonists be paused before elective procedures: 7 days for weekly-dose formulations, the day before for daily-dose formulations. Some institutions have moved to more conservative protocols.

Beyond GLP-1s, other peptides have less-characterized anesthesia interactions but the disclosure principle applies broadly. Peptides affecting clotting, platelet function, blood pressure, or healing should be on the anesthesiology team's radar.

What to actually do

• Always disclose all peptide use to the surgical team, anesthesiologist, and pre-operative nursing — explicitly. "Are you on any medications?" disclosure questions often don't capture peptides because patients don't think of them as medications.
• For GLP-1 agonists specifically: pause weekly formulations 7 days before procedures requiring sedation, daily formulations the day before. Ask the surgical team for institution-specific guidance.
• For other peptides: the anesthesiology team will guide based on the specific peptide and procedure. The principle is disclosure, not self-deciding.
• BPC-157, TB-500, and other healing peptides may interact with healing and inflammation patterns post-surgery in ways not well-characterized. Disclosure lets surgeons plan accordingly.
• Anticoagulant peptides or peptides with bleeding considerations warrant pre-operative review.

If you have personal or family cancer history

The interaction

Several peptide categories warrant particular caution in cancer survivorship or strong family cancer history:

• Growth-axis peptides elevate IGF-1 levels. IGF-1 is mitogenic for many cell types and elevated levels have epidemiological associations with certain cancers (prostate, breast, colorectal). For active cancer or recent cancer treatment, growth-axis peptides are generally inappropriate. For long-term cancer survivors, oncologist input is the right framework. The relevant peptides: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, Hexarelin, MK-677, IGF-1 LR3, MGF.
• Angiogenic peptides — BPC-157, TB-500, GHK-Cu systemically — promote vascular growth that could theoretically support tumor vascularization. The mechanism is theoretical concern, not documented harm in cancer survivors, but for active cancer the concern is acute.
• Melanotan II is specifically inappropriate for melanoma history — the mechanism activates the same melanocortin receptors implicated in melanoma biology.
• Hormonal peptides — particularly anything affecting growth hormone, IGF-1, or sex steroids — warrant oncologist input for cancer survivors.

What to actually do

• Oncologist input is the right decision pathway for any peptide use in cancer survivorship contexts. The community-standard recommendations don't apply.
• The growth-axis peptides specifically have enough theoretical concern that the default should be avoidance unless there's an oncologist sign-off for a specific indication.
• For healing peptides (BPC-157, TB-500, copper peptides), the angiogenesis concern is less acute for survivors in remission, but oncologist input is still appropriate.
• If you're in active treatment (chemotherapy, radiation, immunotherapy), the appropriate framing is "no peptides" unless your oncology team specifically advises otherwise.

If you take anticoagulants (warfarin, DOACs, antiplatelet agents)

The interaction

Peptides with angiogenic effects, platelet effects, or bleeding implications warrant caution alongside anticoagulants:

• BPC-157 and TB-500 have angiogenic and tissue-remodeling effects with theoretical bleeding considerations.
• Copper peptides (GHK-Cu, AHK-Cu) affect clotting in some studies; clinical significance at typical doses is unclear.
• VIP, KPV, and other anti-inflammatory peptides have variable effects on platelet function.
• Most cosmetic-grade topical peptides have minimal systemic exposure and minimal anticoagulant interaction.

What to actually do

• If on warfarin, monitor INR more frequently when adding any peptide. Unexpected changes warrant peptide review and possible discontinuation.
• If on DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), routine monitoring isn't standard but bleeding signs warrant attention.
• For elective procedures, discuss all peptide use with the anticoagulation management team well in advance.
• Topical peptides generally don't require anticoagulant adjustment but disclosure is still appropriate.

If you take antidepressants (SSRIs, SNRIs, MAOIs) or stimulants

The interaction

Several peptides have effects on neurotransmitter systems with potential interactions:

• Selank and Semax have been suggested to have serotonergic effects in some research. For users on MAOIs the theoretical interaction is most acute; for SSRIs/SNRIs the concern is theoretical but worth flagging. Clinical evidence of actual harm is thin.
• Tesofensine is itself a triple monoamine reuptake inhibitor — combining with other monoamine-affecting medications (SSRIs, MAOIs, stimulants, decongestants) creates substantial interaction surface. For Tesofensine users on these medications, careful prescriber coordination is required.
• PT-141 / Bremelanotide activates melanocortin receptors and may have mood effects; interactions with mood-affecting medications are theoretically possible.
• 5-Amino-1MQ affects methylation pathways that intersect with neurotransmitter synthesis; theoretical interaction with SSRIs is plausible but uncharacterized.
• Dihexa, Cerebrolysin, Cortexin, and other nootropic peptides may have interactions with mood medications worth discussing with prescribers.

What to actually do

• MAOI users should be most cautious — the serotonin syndrome risk from combining serotonergic agents with MAOIs is genuinely dangerous. For Tesofensine specifically, MAOI use is essentially a contraindication.
• SSRI/SNRI users should disclose peptide use to prescribing psychiatrists and watch for mood/anxiety changes during peptide initiation.
• Stimulant users (Adderall, Vyvanse, dexmethylphenidate) should be cautious about Tesofensine specifically and discuss other peptides with prescribers.
• Disclosure principle applies broadly — psychiatrists need to know about peptides for medication management decisions.

If you take thyroid medications

The interaction

Several peptides affect thyroid function or interact with thyroid medication absorption:

• Growth-axis peptides can affect thyroid hormone metabolism through GH-IGF-1 axis effects on T4-to-T3 conversion.
• Glutathione, NAD+ precursors, and antioxidant compounds can affect thyroid hormone levels in some patients.
• Levothyroxine absorption is sensitive to timing relative to other oral compounds — separate by at least 4 hours.

What to actually do

• Check TSH 6-8 weeks after starting any peptide that might affect thyroid function, particularly growth-axis peptides.
• Continue normal levothyroxine timing (typically first thing in the morning, separated from food and other medications).
• If thyroid symptoms change (fatigue, weight changes beyond what the peptide explains, cold intolerance, mood changes), get TSH checked.

If you have kidney or liver disease

The interaction

Renal and hepatic impairment affect peptide clearance, particularly for compounds metabolized or excreted through these organs:

• GLP-1 receptor agonists are generally safe in mild-moderate renal impairment but require dose adjustment or avoidance in severe renal disease. Liver disease is less of an issue for most GLP-1s.
• Most peptides have limited characterization in renal or hepatic impairment populations because the trial populations excluded these patients.
• Specific concerns: anything cleared renally requires consideration in CKD; anything affecting protein synthesis requires consideration in hepatic disease.

What to actually do

• Nephrologist or hepatologist input is appropriate for any peptide use in significant renal or hepatic disease.
• The honest framing is "the safety profile for most peptides in these populations is uncharacterized" — community recommendations don't apply.
• Dose reduction may be appropriate even for peptides not formally studied in these populations.

If you're pregnant, breastfeeding, or trying to conceive

The interaction

Almost no peptide has adequate human safety data during pregnancy or breastfeeding. This includes FDA-approved peptides — most carry Category C or higher pregnancy designations or were never tested in pregnant populations.

What to actually do

• Default to no peptide use during pregnancy or breastfeeding unless your obstetrician specifically advises otherwise for a defined clinical indication.
• If trying to conceive, stop most peptides before conception attempts. Peptide clearance and washout periods vary; obstetric input on timing is appropriate.
• Specific concerns: GLP-1 receptor agonists should be discontinued ahead of planned pregnancy (FDA recommends at least 2 months before). Growth-axis peptides should be discontinued. Hormonal peptides should be discontinued.
• Topical cosmetic peptides (cosmetic-grade GHK-Cu, AHK-Cu, etc.) have less systemic exposure but the default should still be discussion with obstetrics rather than self-decision.

If you have cardiovascular disease

The interaction

Several peptide categories warrant cardiovascular consideration:

• GLP-1 receptor agonists have favorable cardiovascular outcomes data in trials. For patients with established CV disease, they may be cardioprotective. Heart rate elevation (modest) is documented.
• Tesofensine has cardiovascular signals — elevated heart rate, blood pressure changes. Inappropriate without cardiac monitoring.
• Sympathomimetic effects from various nootropics can affect blood pressure and heart rate.
• Anticoagulant/antiplatelet interactions matter for CV patients on these medications.

What to actually do

• Cardiologist input for significant CV disease before starting peptides.
• Baseline cardiovascular metrics before starting (BP, resting HR, ECG if indicated).
• Monitor during initiation — particularly for peptides with known CV effects.

If you have autoimmune disease or take immunosuppressants

The interaction

Immunomodulatory peptides have potential interactions with both the disease and the medications used to treat it:

• Thymosin Alpha-1, Thymalin activate aspects of immune function — potentially beneficial in some autoimmune contexts, potentially counterproductive in others. Rheumatologist input is appropriate.
• BPC-157, KPV have anti-inflammatory effects that could affect immunosuppressant dosing.
• Cytokine-modulating peptides require careful integration with existing autoimmune treatment.

What to actually do

• Rheumatologist or immunologist input for any peptide use in autoimmune contexts.
• Disease flare monitoring — autoimmune diseases can flare during immune-modulatory peptide initiation.
• The honest framing is that autoimmune disease + research-grade peptides is a context where clinician oversight isn't optional.

The disclosure principle

The thread connecting all of this: disclosure to your clinicians is the cornerstone of peptide safety when access happens outside formal prescribing channels.

Most peptide users access peptides outside their primary-care or specialist prescribing flow. That's a defensible practical choice for many peptides, but it bypasses the pharmacist screening, the EHR interaction flagging, and the prescriber medication-list review that catch interactions in conventional medicine. Disclosing peptide use to your clinicians — primary care, specialists, surgical teams, anesthesiologists, dentists — restores that safety layer manually.

The disclosure doesn't have to invite medical recommendations about whether to use the peptide. The clinician's job in the disclosure is to identify interactions and contraindications relevant to their specialty. Many users don't disclose because they expect pushback or recommendations against use. The cost of that non-disclosure is missing the interactions that matter.

The bottom line

Peptide drug interactions are the most underappreciated safety risk in peptide use because most users access peptides outside the prescribing channels where interaction screening happens. The clinically meaningful interactions cluster into identifiable categories: GLP-1s plus diabetes medications (hypoglycemia), GLP-1s plus opioids (gastroparesis), GLP-1s plus anesthesia (aspiration), growth-axis peptides plus cancer history (theoretical mitogenic concern), angiogenic peptides plus anticoagulants (theoretical bleeding consideration), serotonergic peptides plus mood medications (theoretical serotonin syndrome risk), and pregnancy as a near-universal contraindication.

For each category, the appropriate response is clinician input rather than community-standard guidelines. The general framing that peptides are reasonably safe at responsible doses from reliable sources remains accurate for healthy adults — but drug interactions and specific medical histories are where that general framing fails to capture individual risk.

Together with our pillar safety article and our high-caution peptides article, this guide covers the safety landscape with the specificity that responsible peptide use requires when access happens outside formal medical channels.